Cingulate Inc. Proceeds from Notes Payable
Cingulate Inc. (CING) reported Proceeds from Notes Payable of $6.00 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-18.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromNotesPayable · last filed 2026-03-18
- Cingulate Inc. proceeds from notes payable for the quarter ending 2023-12-31 was $0.00.
- Cingulate Inc. proceeds from notes payable for the quarter ending 2023-09-30 was $0.00.
- Cingulate Inc. proceeds from notes payable for the quarter ending 2022-12-31 was $0.00.
- Cingulate Inc. proceeds from notes payable for the quarter ending 2021-03-31 was $69.79K.
- Cingulate Inc. proceeds from notes payable for fiscal 2025 was $6.00M, a 20.87% increase from fiscal 2024.
- Cingulate Inc. proceeds from notes payable for fiscal 2024 was $4.96M, a 65.47% increase from fiscal 2023.
- Cingulate Inc. proceeds from notes payable for fiscal 2023 was $3.00M, a 40.00% decline from fiscal 2022.
- Cingulate Inc. proceeds from notes payable for fiscal 2022 was $5.00M.
| Period end | Proceeds from Notes Payable 3 month | Proceeds from Notes Payable 6 month | Proceeds from Notes Payable 9 month | Proceeds from Notes Payable 12 month |
|---|---|---|---|---|
| 2025-12-31 | $6.00M 10-K · filed 2026-03-18 | |||
| 2024-12-31 | $4.96M 10-K · filed 2026-03-18 | |||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $0.00 derived: sum of 2 quarters · filed 2025-03-27 | $3.00M 10-K · filed 2025-03-27 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $3.00M 10-Q · filed 2024-11-07 | ||
| 2023-06-30 | $3.00M 10-Q · filed 2024-08-13 | |||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | $5.00M 10-K · filed 2024-04-01 | ||
| 2022-09-30 | $5.00M 10-Q · filed 2023-11-13 | |||
| 2021-03-31 | $69.79K 10-Q · filed 2022-05-12 | |||
| 2020-12-31 | $954.00K 10-K · filed 2022-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |